Diazyme kits incorporate PNA (peptide nucleic acid) technology:
This article was originally published in Clinica
The Diazyme Laboratories division of General Atomics (La Jolla, California) introduced SNP detection kits for Factor V Leiden and MTHFR C667T at the American Association of Clinical Chemistry meeting in Chicago, Illinois last week. The kits incorporate peptide nucleic acid (PNA) technology licensed from Boston Probes (Bedford, Massachusetts). Factor V Leiden is the most common inherited coagulation disorder in the US population, and increases the risk of venous thrombosis in homozygous individuals up to 140-fold. The MTHFR C667T mutation is linked with DVT, heart attack and stroke.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.